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Background: Chronic bronchitis (CB) is often misdiagnosed or diagnosed at a later stage of 
chronic obstructive pulmonary disease (COPD). We examined how this later diagnosis may 
impact health care costs and utilization during the 12 months prior to and 24 months post initial 
CB diagnosis.
Methods: This retrospective case-control analysis used claims data from a large US database 
from July 1, 2003 through June 30, 2007. Patients with CB aged 40 years and older were 
  propensity matched (N = 11,674) to patients without evidence of COPD or asthma by demo-
graphics, CB diagnosis quarter/year, and comorbidities. Group differences were assessed using 
Student’s t-test and Pearson chi-square test statistics.
Results: Six months prediagnosis, CB patients had higher frequencies of any hospitalization 
(9.6%, 6.7%; P , 0.05), emergency department/urgent care visits (13.3%, 6.7%; P , 0.05), 
and prescriptions (97.3%, 94.1%; P , 0.05). Six months postdiagnosis, CB patients had 5.6 
times more hospitalizations (P , 0.05) and 3.1 times more emergency department/urgent care 
visits (P , 0.05) compared with controls. Mean total costs (US$) for CB patients 12 months 
prediagnosis were significantly higher than controls (months 12–7: $4212, $3826; P , 0.05; 
months 6–1: $5289, $4285; P , 0.05). CB patients had higher mean total costs ($8919; 
P , 0.05) 6 months postdiagnosis. Costs remained $2429 higher for CB patients 19–24 months 
postdiagnosis (P , 0.05).
Conclusion: Health care costs and utilization among CB patients are increased both prior to 
diagnosis and during the 2 years postdiagnosis. This study suggests that not accurately   diagnosing 
CB early has a substantial impact on health care costs, and that the economic burden for CB 
patients remains elevated even after adjustment for comorbidities associated with COPD.
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Introduction
Chronic bronchitis (CB), an inflammatory condition that affects the central bronchi, is 
one of two main lung diseases by which patients with chronic obstructive pulmonary 
disease (COPD) are characterized. Excessive mucus secretion differentiates it from 
the second, emphysema, which is characterized by permanent enlargement of lung 
airways and destruction of the walls of the alveoli, making breathing difficult.1 Other 
symptoms of CB related to lung inflammation and heavy mucus production include 
cough, production of sputum, and dyspnea.1 In 2008, more than 9.8 million Americans 
reported having a CB diagnosis.2 While many patients with COPD may suffer from 
both conditions, the courses of the diseases and response to treatment are frequently 
different; separate studies of outcomes between the two could assist in optimizing 
care for these patients.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Estimated annual expenditures for CB treatment total 
US$11.7 billion, with hospitalizations accounting for 
US$6 billion of the total costs.3 There are limited studies 
that examine the costs associated with CB, but research 
has shown that hospitalizations for acute CB exacerba-
tions accounted for 46%–90% of the costs associated with 
treatment.4 The diminished quality of life experienced by 
COPD patients is well documented and suggests that earlier 
detection, treatment, and reduction of exacerbations may 
have a substantial economic and psychosocial impact on 
patients.5–13
The chronic cough and sputum production associated with 
CB often predates the development of airflow limitation.14 
The GOLD (Global Initiative for Chronic Obstructive Lung 
Disease) guidelines for diagnosis and treatment of COPD 
  recommend early identification of patients with symptoms 
of CB in order to begin intervention at the   earliest stage of 
COPD.14 Unfortunately, CB symptoms may be dismissed by 
patients as “smoker’s cough”, or physicians may   misdiagnose 
CB as acute bronchitis or asthma.15,16 Once CB is diagnosed 
and treatment has commenced, many patients have progressed 
into more severe COPD stages, resulting in higher consump-
tion of health care resources and increased complexity in 
clinical management.
Prior research demonstrated higher utilization rates of 
health care resources for COPD patients when compared 
with a control population during the 12 months preceding 
initial COPD diagnosis.17 Utilization trends indicated an 
increasing use of resources in terms of medical services 
and pharmacy prescriptions up to the COPD diagnosis, 
particularly in the final month before diagnosis.17 In addi-
tion, total costs for COPD patients have been shown to be 
higher up to 2 years prior to diagnosis.18 To determine if 
these trends were apparent for the subset of COPD patients 
diagnosed with CB, we examined health care utilization and 
costs for 12 months prior to CB diagnosis and 24 months 
post diagnosis.
Data and methods
study design and data source
This case–control analysis used data from the PharMetrics 
Integrated Database, which contains continuously updated 
information from enrollment files and facility, professional 
services, and outpatient pharmacy claims from more than 
90 participating US health plans, representing more than 
55 million patients. The data include dates of service and 
International Classification of Diseases, 9th   Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes, 
  participating plan payment and billed charge information. 
The dataset is deidentified and Health Insurance Portability 
and   Accountability Act (HIPAA) compliant.
sample
CB and control cohorts were selected using medical 
claims data for services provided between July 1, 2003 
and June 30, 2007. The CB cohort consisted of patients 
with an initial primary or secondary diagnosis claim of 
CB (ICD-9-CM codes 491.xx), considered the index 
event, during the observation period described above. All 
study patients were required to be aged 40 or older and 
to have had continuous enrollment in a health plan for at 
least 12 months prior to the initial diagnosis (index date). 
Thus the earliest index date was July 1, 2004. In addition 
to the preindex health plan enrollment period, s  ubjects 
were also required to remain enrolled in a health plan for a 
minimum of 1 year, to have at least one prescription claim 
in both the pre- and postindex observational time periods 
(to provide evidence of pharmaceutical insurance cover-
age) and to have no prior claims for any COPD-related 
outpatient visit.
Patients in the potential control cohort had at least 
36 months of continuous enrollment between July 1, 2003 and 
June 30, 2007. Index dates were randomly assigned to control 
cohort subjects following the first 12 months of continuous 
enrollment. Patients in the potential control cohort had no 
evidence of bronchitis, chronic bronchitis, emphysema, 
asthma, or unspecified COPD (ICD-9-CM codes 490.xx, 
491.xx, 492.xx, 493.xx, 496.xx) during the 12 months prior 
to the randomly assigned index date, and also had to have at 
least one medical services claim and one prescription claim 
pre- and postindex date. Patients with serious lung condi-
tions other than COPD or asthma were excluded from both 
cohorts.19 The likelihood of a CB diagnosis was calculated by 
a logistic regression that controlled for demographics (age, 
sex, and geographic region), quarter and year of index date, 
and comorbidities (Table 1). CB patients were propensity 
matched one-to-one to control subjects using the greedy 
match algorithm, a method that derives matched samples 
using nearest available pair matching.20,21 CB cases were 
matched to controls according to age, geographic region, 
quarter of year of index date, and selected comorbidities to 
reduce selection bias. Comorbid conditions were identified 
based on the classifications by Elixhauser et al22 sleep apnea 
and heart disease (rheumatic heart failure, hypertensive heart 
disease, ischemic heart disease, and unspecified cardiovas-
cular disease) were also included.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
75
economic burden of chronic bronchitis
Table 1 Case patients and control subject characteristics before and after propensity matching
Characteristic Pre-matching Post-matching
Cases Controls Cases Controls
N (%) N (%) N (%) N (%)
number of patients 11937 280264 11674 11674
Age, yrs (mean, sD) 61.8 12.2 57.2 10.9 61.5 12.1 61.8 12.1
sex
  Male 4944 (41.4%) 119264 (42.6%) 4832 (41.4%) 5017 (43.0%)b
  Female 6993 (58.6%) 161000 (57.4%) 6842 (58.6%) 6657 (57.0%)b
region
  Midwest 2093 (17.5%) 77533 (27.7%) 2082 (17.8%) 2010 (17.2%)
  northeast 4515 (37.8%) 67901 (24.2%) 4334 (37.1%) 4308 (36.9%)
  south 3315 (27.8%) 71932 (25.7%) 3269 (28.0%) 3301 (28.3%)
  West 2014 (16.9%) 62898 (22.4%) 1989 (17.0%) 2055 (17.6%)
Quarter and year of the index date
  Q3-2004 1210 (10.1%) 48236 (17.2%) 1201 (10.3%) 1227 (10.5%)
  Q4-2004 1677 (14.0%) 50105 (17.9%) 1657 (14.2%) 1664 (14.3%)
  Q1-2005 2337 (19.6%) 50674 (18.1%) 2288 (19.6%) 2254 (19.3%)
  Q2-2005 1472 (12.3%) 26573 (9.5%) 1438 (12.3%) 1440 (12.3%)
  Q3-2005 1140 (9.6%) 27554 (9.8%)a 1113 (9.5%) 1144 (9.8%)
  Q4-2005 1499 (12.6%) 27028 (9.6%) 1465 (12.5%) 1474 (12.6%)
  Q1-2006 1588 (13.3%) 25707 (9.2%) 1524 (13.1%) 1529 (13.1%)
  Q2-2006 1014 (8.5%) 24387 (8.7%)a 988 (8.5%) 942 (8.1%)
Comorbid conditions
  Asthma* 2722 (22.8%) 2660 (22.8%)
  Alcohol abuse 152 (1.3%) 1498 (0.5%) 139 (1.2%) 135 (1.2%)
  Blood loss anemia 121 (1.0%) 1406 (0.5%) 108 (0.9%) 96 (0.8%)
  Cardiac arrythmia 1348 (11.3%) 14709 (5.2%) 1210 (10.4%) 1243 (10.6%)
  Congestive heart failure 1083 (9.1%) 4979 (1.8%) 856 (7.3%) 785 (6.7%)
  Coagulopathy 245 (2.1%) 2457 (0.9%) 217 (1.9%) 204 (1.7%)
  Cardiovascular disease 185 (1.5%) 2041 (0.7%) 168 (1.4%) 186 (1.6%)
  Deficiency anemias 1005 (8.4%) 14636 (5.2%) 921 (7.9%) 949 (8.1%)
  Depression 970 (8.1%) 16865 (6.0%) 928 (7.9%) 929 (8.0%)
  Diabetes 2380 (19.9%) 37144 (13.3%) 2247 (19.2%) 2265 (19.4%)
  Fluid and electrolyte disorders 792 (6.6%) 7268 (2.6%) 685 (5.9%) 676 (5.8%)
  hypertension (complicated) 600 (5.0%) 5605 (2.0%) 531 (4.5%) 531 (4.5%)
  hypertension (uncomplicated) 5867 (49.1%) 105482 (37.6%) 5644 (48.3%) 5671 (48.6%)
  hypothyroidism 1238 (10.4%) 26781 (9.6%) 1199 (10.3%) 1245 (10.7%)
  Ischemic heart disease 2411 (20.2%) 25481 (9.1%) 2215 (19.0%) 2293 (19.6%)
  Liver disease 235 (2.0%) 3278 (1.2%) 213 (1.8%) 212 (1.8%)
  Obesity 543 (4.5%) 7678 (2.7%) 500 (4.3%) 556 (4.8%)
  Other neurological disorders 421 (3.5%) 5777 (2.1%) 381 (3.3%) 383 (3.3%)
  Paralysis 89 (0.7%) 906 (0.3%) 77 (0.7%) 87 (0.7%)
  Peripheral vascular disorders 950 (8.0%) 3711 (1.3%) 838 (7.2%) 837 (7.2%)
  Psychoses 706 (5.9%) 10368 (3.7%) 670 (5.7%) 677 (5.8%)
  Pulmonary circulation disorders 139 (1.2%) 560 (0.2%) 92 (0.8%) 88 (0.8%)
  renal failure 357 (3.0%) 3209 (1.1%) 296 (2.5%) 277 (2.4%)
  rheumatic heart failure 7 (0.1%) 37 (0.0%) 4 (0.0%) 4 (0.0%)
    rheumatoid arthritis/collagen 
vascular
525 (4.4%) 8154 (2.9%) 503 (4.3%) 522 (4.5%)
  Obstructive sleep apnea 628 (5.3%) 7919 (2.8%) 580 (5.0%) 580 (5.0%)
    Peptic ulcer excluding  
bleeding
120 (1.0%) 1486 (0.5%) 115 (1.0%) 112 (1.0%)
  Valvular disease 1032 (8.6%) 11913 (4.3%) 924 (7.9%) 972 (8.3%)
  Weight loss 51 (0.4%) 306 (0.1%) 37 (0.3%) 41 (0.4%)
Notes: Propensity score calculated as probability of chronic bronchitis diagnosis using a logistic regression controlling for demographics (age, sex, region), quarter and year 
of the index date, and comorbid conditions listed. *Asthma was specifically excluded in the control population; aNo signficant difference between chronic bronchitis (CB) 
cohort and control cohort at level of 0.05; bSignficant difference between CB cohort and control cohort at level of 0.05. Q1, July 1 to Sept 30, Q2, Oct 1 to Dec 31, Q3, Jan 
1 to March 31, Q4, April 1 to June 30.
Abbreviation: sD, standard deviation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Measures
Utilization and costs due to all causes in both the pre- and 
postindex periods were categorized by inpatient hospital-
ization (IP), emergency department/urgent care (ED/UC), 
outpatient visits (OP), and pharmacy fills. Utilization and 
costs occurring on the index date were included in the first 
6-month period postindex. We defined costs as the amount 
paid by the health plan; costs paid by other sources were not 
included. Costs for IP, OP, and ED/UC were aggregated as 
medical services costs. Pharmacy costs were kept separate; 
total costs were the sum of medical services and pharmacy 
costs. Each category for both cohorts was analyzed for six 
time periods of 6 months each: two in the preindex period 
and four during the postindex period.
Analysis
Descriptive analysis was used for all demographic, patient 
comorbidity, and outcome variables. Continuous variables 
were reported as means, standard deviations, and medians. 
Binary and categorical variables were reported as counts 
and percentages.
Means and frequencies for utilization and costs were 
calculated and compared for all outcome categories in both 
the pre- and postindex periods. Covariate adjustment was 
incorporated through the use of a propensity score matching 
technique as previously described. The Student’s t-test and 
Wilcoxon rank-sum test was used for continuous variables 
and the Pearson chi-square test for binary use variables. All 
statistical tests were two-sided with a 0.05 level of signifi-
cance. Analyses were conducted with SAS software (version 
9.1.3 for Windows; SAS Institute, Cary, NC).
Results
There were initially 182,169 patients who had a COPD 
diagnosis at any time; after selection criteria were applied, 
11,937 patients met criteria for the CB cohort. A 10% random 
sample of possible control subjects with 3 or more years of 
continuous enrollment was selected, of whom 282,078 met 
the control cohort selection criteria. These patients were 
randomly reduced to a pool of 65,654 control patients. 
Propensity score matching was used to match CB patients 
to control patients on a one-to-one basis, resulting in two 
cohorts of 11,674 each.
Prior to matching, the two cohorts exhibited significant 
differences in all matching characteristics with the exception 
of two of the index date quarter variables (Table 1). After 
matching, the CB patient cohort and control patient cohort 
exhibited a significant difference only in the   percentage of 
each population that was male (CB = 41.4%, control = 43.0%; 
P = 0.0142). The cohorts were similar with respect to comor-
bidities, geographic region, mean age, and quarter in which 
the index date occurred.
After matching, the mean age of patients in the CB cohort 
was 61.5 years; for the controls, 61.8 years. Patients were 
predominantly from the Northeast (37%) and female (57.8%). 
The most prevalent comorbidities in each cohort were: 
uncomplicated hypertension (48.5%), diabetes (19.3%), 
ischemic heart disease (19.3%), arrhythmia (10.5%), and 
hypothyroidism (10.5%), shown in Table 1. Among the CB 
cohort, 22.8% had a history of asthma in addition to their 
CB diagnosis.
There was a decrease in the number of patients with 
continuous enrollment beginning 13 months after the index 
date. Approximately 23% of the CB patients were lost 
to follow-up during months 13–18, and another 25% in 
the 19–24 month period after the index date. For the final 
6-month observation period (months 19–24), there were 6128 
CB patients and 6203 control patients.
As shown in Table 2 and Figure 1, from 1 year and up to 
6 months prior to the CB diagnosis there were no differences 
between the cohorts with respect to the percentage of patients 
having any IP visit; however, the CB cohort had a higher 
percentage having any ED/UC visit (9.5%, 6.4%; P , 0.05), 
and any pharmacy use (93.4%, 91.5%; P , 0.05), while 
having a lower percentage with any OP visit (90.5%, 92.9%; 
P , 0.05). In the next 6 months, which was the 6 months 
immediately prior to diagnosis, patients in the CB cohort, 
compared with the control cohort, had a higher percentage 
having any IP visit (9.6%, 6.7%; P , 0.05), and again, higher 
percentages for any ED/UC visit (13.3%, 6.7%; P , 0.05), 
and any pharmacy prescription (97.3%, 94.1%; P , 0.05). 
Percentages of patients having any OP visit were identical 
for the two cohorts during the 6 months immediately prior 
to CB diagnosis.
During the first 6 months postindex (Figure 1), patients 
in the CB cohort had 5.6 times more IP visits (30.4%, 5.4%; 
P , 0.05) and 3.1 times more ED/UC visits (20.7%, 6.6%; 
P , 0.05). To a lesser degree, OP visits and pharmacy use 
were also higher for the CB cohort. Utilization rates remained 
higher for the CB cohort during all four of the 6-month 
periods postindex, but beginning in the second 6-month 
postindex period, utilization rates in the CB cohort declined 
from the highs reached in the first postindex period and 
remained fairly stable for the remaining observation periods. 
The control cohort’s utilization rates declined slightly in 
each of the four postindex periods. Mean number of events International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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were higher for the CB cohort in all time periods, pre- and 
postindex, compared with the control cohort except for mean 
OP visits in the 6-month period immediately preceding the 
CB diagnosis (Table 3, Figure 2).
Mean total costs (US$) for the CB cohort during both 
preindex periods were significantly higher than for the con-
trol cohort (months 12–7: $4212, $3826; P , 0.05; months 
6–1: $5289, $4285; P , 0.05). Component costs were also 
higher, with the exception that there was no difference in 
medical services costs during the initial 6 months prior 
to diagnosis (Table 4). CB patients had higher mean total 
costs ($8919; P , 0.05) in the 6 months postdiagnosis. 
Costs for both groups then decreased (Figure 3) but for CB 
patients remained $2429 higher than for control patients 
19–24 months postdiagnosis (P , 0.05). Median costs were 
all significantly higher for the CB cohort (Table 5).
Table 2 Chronic bronchitis patients and control subjects with any health care events
Subjects w/any utilization Preindex Postindex
Months prior to index Months after index
7–12* 1–6 1–6 7–12 13–18** 19–24
hospitalization (IP)
  Chronic bronchitis 6.1% 9.6% 30.4% 10.5% 11.0% 10.4%
  Control 6.2% 6.7% 5.4% 6.1% 5.2% 5.7%
eD/UC visit
  Chronic bronchitis 9.5% 13.3% 20.7% 12.2% 12.0% 12.3%
  Control 6.4% 6.7% 6.6% 6.8% 6.6% 6.5%
Outpatient visit (OP)
  Chronic bronchitis 90.5% 93.8% 99.7% 95.2% 94.7% 94.2%
  Control 92.9% 93.8% 94.0% 93.7% 91.7% 91.3%
Pharmacy use
  Chronic bronchitis 93.4% 97.3% 99.0% 95.2% 92.7% 91.0%
  Control 91.5% 94.1% 93.7% 92.5% 87.7% 85.4%
Notes: All percentages were significantly different at a 0.05 level using a chi-square test except for IP visits in pre-index months 12–7 and OP visits in pre-index   
months 6–1.
*n = 11674 CB and controls months 12–1 preindex and months 1–12 postindex; **n = 9009 CB, 9305 controls months 13–18 postindex; n = 6128 CB, n = 6203 controls 
months 19–24 postindex.
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Figure 1 Incidence of any utilization for all-cause health care events.
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Table 3 Total and mean events for chronic bronchitis and control populations
Preindex Postindex
Months prior to index Months after index
7–12* 1–6 1–6 7–12 13–18** 19–24
Total events
IP
  Chronic bronchitis 873 1,378 4,687 1,633 1,333 866
  Control 900 973 759 885 593 466
ED/UC visit
  Chronic bronchitis 1,502 2,156 3,552 2,154 1,595 1,078
  Control 962 1,005 968 1,048 767 538
OP
  Chronic bronchitis 99,773 110,543 167,877 129,531 99,122 64,805
  Control 92,485 97,590 94,172 94,695 72,450 48,416
Pharmacy use
  Chronic bronchitis 220,580 237,961 288,189 256,939 192,569 126,730
  Control 148,984 155,404 156,901 157,332 120,687 80,716
Mean events
IP
  Chronic bronchitis 0.07 0.12 0.40 0.14 0.15 0.14
  Control 0.08 0.08 0.07 0.08 0.06 0.08
ED/UC visit
  Chronic bronchitis 0.13 0.18 0.30 0.18 0.18 0.18
  Control 0.08 0.09 0.08 0.09 0.08 0.09
OP
  Chronic bronchitis 8.55 9.47 14.38 11.10 11.00 10.58
  Control 7.92 8.36 8.07 8.11 7.79 7.81
Pharmacy use
  Chronic bronchitis 18.90 20.38 24.69 22.01 21.38 20.68
  Control 12.76 13.31 13.44 13.48 12.97 13.01
Notes: Numbers of events were significantly different at a 0.05 level using a Wilcoxon Rank Sum test except for IP visits in preindex months 12–7. 
*n = 11674 CB and controls months 12–1 preindex and months 1–12 postindex; **n = 9009 CB, 9305 controls months 13–18 postindex; n = 6128 CB, n = 6203 controls 
months 19–24 post-index.
Abbreviations: eD/UC, emergency department/urgent care; IP, inpatient hospitalization; OP, outpatient visits.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Discussion
This retrospective observational study demonstrated that total 
health care utilization and costs for CB patients in the US 
are significantly greater than for a matched control cohort 
of patients. This was true for both the 12-month period 
prior to CB diagnosis and for 2 years after diagnosis. Mean 
utilization and costs in the CB cohort were seen to increase 
in the 6 months immediately preceding diagnosis, a similar 
finding to that of Akazawa et al.17 This prediagnosis trend is 
commensurate with the gradual progression of COPD.
In the postindex period, the majority of total health 
care cost differences between the cohorts were for medical 
services. Patients in the CB cohort incurred approximately 
US$2000–$2800 more for medical services across three 
of the 6-month postindex periods. During the same periods, 
the CB cohort’s pharmacy costs were US$500–$600 higher 
than the control cohort. After the initial spike following 
a   diagnosis of chronic bronchitis, medical services costs 
declined but remained elevated compared with controls, 
which may be due to increased utilization related to CB 
events, but also to non-CB related health events.
Prevalence of various comorbidities has been documented 
generally in studies of COPD patients, but there is a dearth of 
information concerning the extent to which comorbid condi-
tions exist in patients with chronic bronchitis. Mapel et al 
found that in an analysis of a population in which 39% had 
cardiovascular disease and 13% had diabetes, the presence 
of comorbid conditions was a better predictor of future 
costs of COPD patients compared with COPD disease stage 
as measured by spirometry.23 Similar prevalence rates of 
comorbidities have been found in other study populations. 
In a telephone survey of COPD patients, Barr et al found 
prevalence rates of more than 50% for hypertension and more 
than 25% for both depression and diabetes.24 A 2005 review 
of 1090 Canadian patients with COPD levels ranging from 
asymptomatic to severe identified comorbidity rates of 51% 
for hypertension, 19% for diabetes, 15% for depression, 
13% for peripheral vascular disease, and 10% for asthma.25 
Our CB cohort had a higher asthma rate compared with the 
COPD patients of the Canadian study, 23% versus 10%, 
respectively; however, in a study of CB patients who were 
initiating maintenance therapy, Delea et al found an asthma 
comorbidity rate of 29%, a prevalence rate similar to CB 
subjects in this analysis.26
Table 4 Mean costs (Us$) for chronic bronchitis and control populations
Preindex Postindex
Months prior to index Months after index
7–12* 1–6 1–6 7–12 13–18** 19–24
Total cost
  Chronic bronchitis $4,212 $5,289 $12,781 $7,101 $7,448 $6,925
  Control $3,826 $4,285 $3,862 $4,070 $4,090 $4,496
Medical services cost
  Chronic bronchitis $3,045 $4,034 $11,193 $5,562 $5,894 $5,415
  Control $3,048 $3,438 $2,957 $3,152 $3,138 $3,520
Pharmacy cost
  Chronic bronchitis $1,167 $1,255 $1,588 $1,539 $1,554 $1,510
  Control $778 $847 $905 $917 $952 $976
Notes: All cost distributions were significantly different at a 0.05 level using Wilcoxon rank-sum test. 
*n = 11674 CB and controls months 12–1 preindex and months 1–12 postindex; **n = 9009 CB, 9305 controls months 13–18 postindex; n = 6128 CB, n = 6203 controls 
months 19–24 postindex.
$0
12–7 6–1
Preindex
(months)
Postindex
(months)
1–6 7–12 13–18 19–24
12–7 6–1
Preindex
(months)
Postindex
(months)
1–6 7–12 13–18 19–24
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
Chronic bronchitis
Control
Medical services all-cause costs
Pharmacy all-cause costs
M
e
a
n
 
c
o
s
t
s
$0
$200
$400
$600
$1,000
$800
$1,400
$1,200
$1,800
$1,600
M
e
a
n
 
c
o
s
t
s
Chronic bronchitis
Control
Figure 3 Mean costs (Us$) for chronic bronchitis and control populations.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
80
Blanchette et al
Similar to a study of COPD patients by Akazawa and 
colleagues, our study found higher IP, ED/UC, and pharmacy 
utilization in the 6 months prior to CB diagnosis; higher 
ED/UC and pharmacy utilization was also observed even 
earlier, up to 1 year prediagnosis. The utilization differences 
became pronounced in the 6 months immediately preceding 
CB diagnosis, reached an apex during the next 6 months that 
included the index date (diagnosis), and then decreased. How-
ever, during the last three of the 6-month periods postindex, 
differences in mean medical services and pharmacy costs, as 
well as mean events, remained at levels of greater magnitude 
than those shown during both 6-month periods prior to CB 
diagnosis. This suggests that there is strong evidence that 
the systemic consequences of chronic bronchitis may play a 
significant role in driving up total health care utilization and 
costs among patients with chronic bronchitis.
A strength of our study is that we focused on adults aged 
40 years and over, as opposed to an exclusively elderly 
population. An additional strength is that we examined health 
care utilization and costs in comparisons of CB and non-CB 
patients, whereas most of the literature has focused on the 
broader definition of COPD. A review by Maciewicz et al 
suggested that the varied aspects of the progression of 
COPD may be related to the aging process;27 earlier disease 
identification and treatment initiation may improve patients’ 
long-term health and economic outcomes, although the total 
cost savings may be modest due to shorter life expectancy 
for patients with COPD.28
This retrospective study based on claims data is not with-
out limitations. Foremost among these is that the accuracy of 
diagnoses could not be verified. The results and conclusions 
of this study are limited to the population studied and the 
operational definitions of our variables. The analysis is limited 
to those with CB who utilize health care services and the 
representation of CB patients in the database we used of our 
analysis. The geographical representation in this study dif-
fered from what has previously been noted for the USA; that 
is, high prevalence in the South and Midwest.29 In addition, 
cost estimates may vary when different databases are used. 
Data were unavailable on both patient smoking behavior and 
severity of disease among the CB cohort, thus limiting our 
findings regarding drivers of resource utilization and cost.
Conclusion
To our knowledge, this is the first study to use a large enough 
population sample to facilitate propensity score matching 
based on comorbidities. Prior studies have not controlled for 
comorbidity by matching,30 creating potential for residual con-
founding and other biases in case-control comparisons. Our 
method allowed for a cleaner assessment of the true impact 
of CB. The disease burden is greatest during the 6-month 
period following CB diagnosis, but is also high in periods 
preceding the diagnosis. In patients diagnosed with chronic 
bronchitis, compared with patients without evidence of COPD 
or asthma, health care utilization and costs continue to remain 
elevated 2 years after diagnosis. This study suggests that not 
accurately diagnosing CB early may have a substantial impact 
on health care costs, resulting in a higher economic burden 
for CB patients than would otherwise be present.
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